Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVAC/PCa after primary radiotherapy in localized high-risk prostate cancer
2011-004967-65Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Nov 2011
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of DCvac in prostate cancer (PCa) (2 arms), sponsored by SOTIO Biotech. Primary endpoint: PSA failure-free survival rate at 5 years. Started Nov 2011; status: completed.
02
Drugs
DCvac
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2011-004967-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004967-65.